Lymphoma Follicular clinical trials

Explore recruiting lymphoma follicular clinical trials.

Recruiting lymphoma follicular studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoma Follicular trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma

Slovakia, Poland, Spain, Hungary, Romania, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients with indolent Non-Hodgkin's Lymphoma.

Spain, Italy, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2)

Czechia, Belgium, Italy, Spain, France, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)

Finland, Norway, Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Denmark, Hungary, Slovakia, Sweden, Austria, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Czechia, Romania, Austria, Italy, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lymphoma Follicular trials by city

Lymphoma Follicular in Toronto Lymphoma Follicular in Vancouver Lymphoma Follicular in Montreal Lymphoma Follicular in Calgary Lymphoma Follicular in Edmonton Lymphoma Follicular in Ottawa Lymphoma Follicular in Winnipeg Lymphoma Follicular in Quebec City Lymphoma Follicular in Hamilton Lymphoma Follicular in Kitchener Lymphoma Follicular in London Lymphoma Follicular in Halifax Lymphoma Follicular in New York Lymphoma Follicular in Los Angeles Lymphoma Follicular in Chicago Lymphoma Follicular in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease